NicOx to Market AdenoPlus in U.S. to ECPs

Rapid Pathogen Screening, Inc., (RPS) and NicOx, S.A., have entered into a licensing agreement giving NicOx access to RPS's innovative diagnostic tests. The agreement grants NicOx worldwide rights to unique point-of-care tests in the ocular field. The first of these tests is AdenoPlus, which reportedly enables rapid and accurate in-office diagnosis of specific ocular diseases and conditions. It's reportedly an easy-to-use point-of-care diagnostic test that identifies patients with adenoviral conjunctivitis using a small tear sample. It provides a definitive result in only ten minutes, making the correct diagnosis available at the time of the doctor visit rather than relying on only signs and symptoms or waiting for results from a laboratory. The agreement grants NicOx exclusive rights to commercialize AdenoPlus to eye care professionals in the US, as well as full exclusive rights to market the test in the rest of the world. RPS maintains rights to commercialize these ocular tests to primary and urgent care professionals in the US. The agreement also covers two additional diagnostic tests currently in development, one for the combined detection of Adenoviral and allergic conjunctivitis and the other to diagnose ocular herpes. Read more.